Breast Cancer

Antonio Llombart-Cussac, MD, PhD, on the implications of prophylaxis for sacituzumab govitecan–related neutropenia and diarrhea in advanced breast cancer.

Rhenium obisbemeda proved feasible and safe for patients with leptomeningeal metastases in an interim analysis of the phase 1 ReSPECT-LM trial.

Experts provide insights on the first-in-human phase 1 ReDiscovertrial trial, evaluating the mutant-selective PI3Kα inhibitor RLY-2608, which is currently enrolling patients.

Sarah Sammons, MD, discusses treating beyond progression and novel research on PI3K inhibitors in HR-positive, HER2-negative metastatic breast cancer.

Rita Mukhtar, MD, discusses the risk of disease recurrence in patients with invasive lobular carcinoma.

Kara N. Maxwell, MD, PhD, discusses the risk of cancer for males carrying BRCA mutations.

High pCR rates were observed for patients with uncommon breast cancer subtypes who received response-predictive subtype–optimized therapy.

Filipa Lynce, MD, discusses ongoing clinical trials investigating novel combinations in patients with inflammatory breast cancer.

Sarah Sammons, MD, describes how she treats patients with HR-positive, HER2-negative metastatic breast cancer who progressed on prior CDK4/6 inhibitors.

Sara M. Tolaney, MD, MPH, discusses key data on checkpoint inhibitor combinations in metastatic triple-negative breast cancer.

Sara M. Tolaney, MD, MPH discusses ongoing clinical trials investigating the addition of HER2-directed therapies to existing treatment regimens for HER2-positive breast cancer.

A panel of experts offer future perspectives in HR+ breast cancer.

A panel of experts offer perspectives in sequencing ADC-Based therapies in HR+ breast cancer.

Linda Vahdat, MD, discusses recent antibody-drug conjugate data in metastatic triple-negative breast cancer.

VK Gadi, MD, PhD, discusses the challenge of identifying patients with HER2-low disease, emphasizing communication between pathologists and medical oncologists in the diagnostic process.

In case you missed any, below is a recap of every OncLive On Air episode that aired in July 2024.

Sara M. Tolaney, MD, MPH, discusses the ongoing investigation of TROP-2–directed antibody-drug conjugates in triple-negative breast cancer.

Filipa Lynce, MD, discusses the current prognosis of patients diagnosed with inflammatory breast cancer subtypes.

The European Medicines Agency has approved Avzivi, a biosimilar referencing bevacizumab.

In their concluding remarks, Virginia Kaklamani, MD, DSc, and Heather McArthur, MD, summarize their key insights and perspectives on the management of HR+ breast cancer.

The key opinion leaders discuss the current unmet needs in the management of HR+/HER2- metastatic breast cancer and explore potential future directions and strategies that may lead to improved patient outcomes.

A panel of experts discuss ADC-based treatment strategies in HR+ Breast cancer.

A panel of experts discuss treatment advancements targeting the PI3K/AKT pathway in HR+ Breast Cancer.

A panel of experts discuss navigating 2L treatment strategies.

A panel of experts offer perspectives in navigating treatment strategies with CDK4/6 inhibitors.